New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards

About this update from Neonc Technologies Holdings, Inc.

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street , the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) . Under this agreement, NeOnc will be featured in a 12-part national broadcast series , with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network . The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S. This partnership launches at a pivotal time for NeOnc Technologies, following two significant corporate milestones: Breakthrough Science Meets Breakthrough Exposure The integrated media campaign includes: Executive Commentary "NeOnc is entering a new era, not only in terms of medical science but also visibility in the public markets. Their latest IP acquisition and $50 million partnership with Quazar reflect serious momentum," said Vince Caruso , Founder and CEO of New to The Street . "We're proud to provide a media platform that matches their global ambitions and innovations with real-world distribution, every month." About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's lead therapeutics, NEO100™ and NEO212™ , are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California , consisting of issued patents and pending applications related to NEO100, NEO212, and other candidates from the NeOnc patent family for multiple uses, including oncological and neurological conditions. To learn more, visit https://www.neonc.com . About New to The Street Since 2009, New to The Street has been a leading force in financial media, showcasing public and private companies through its unmatched mix of national television broadcasts, digital syndication, and social media reach. With over 3.2 million subscribers on the New to The Street TV YouTube channel and a combined following of more than 511,000 across LinkedIn, Facebook, Instagram, and X , the platform delivers consistent visibility to investors, industry leaders, and the general public. New to The Street offers more linear "real TV" broadcast distribution than any other outlet in the space, with long-running placements across Bloomberg TV , Fox Business Network , and other national platforms. Its "Opportunities to Consider™" segments and in-depth executive interviews have become a trusted source for market-moving narratives, emerging growth stories, and thought leadership across finance, tech, biotech, and beyond. Learn more: Media Contact: Monica Brennan Head of Communications, New to The Street [email protected] SOURCE: New To The Street View the original press release on ACCESS Newswire

View stock analysis, news, and events for Neonc Technologies Holdings, Inc.